RNU7-34P: A Potential Drug Target and Biomarker (G100147821)
RNU7-34P: A Potential Drug Target and Biomarker
Ribonucleotide RNA (RNA) urine has been identified as a promising biomarker for various diseases, including cancer, due to its unique potential for non-invasive diagnosis and personalized medicine. Among the many RNA types, RNA-conversion enzyme RNA polymerase II (RNA-II) has been particularly interest due to its role in the rapid amplification of specific target RNAs, such as RNA-II-containing microRNAs (miRNAs) in cancer.
RNA-II has been shown to be overexpressed or underexpressed in various types of cancer, which has led to its potential as a drug target or biomarker. One of the most promising targets of RNA-II is the protein p16INK4a (EKRAB), which is a key regulator of the T-cell response and has been implicated in various diseases, including cancer.
The p16INK4a gene encodes a 23 kDa protein that plays a crucial role in regulating the expression of genes involved in cell growth, differentiation, and apoptosis. p16INK4a has been shown to be overexpressed in various types of cancer, including breast, ovarian, and colorectal cancers.
RNA-II-containing miRNAs have been shown to play a negative role in the regulation of p16INK4a. miRNA-20, a well-known miRNA that has been shown to target p16INK4a for degradation in various types of cancer, has been shown to reduce the expression of p16INK4a in cancer cells.
RNA-II has also been shown to play a positive role in the regulation of apoptosis, which is a natural response of cells to DNA damage or other stressful conditions. In cancer, the regulation of apoptosis can be exploited as a potential therapeutic approach.
The potential drug target p16INK4a is an attractive target for cancer therapy due to its involvement in various diseases, including cancer. Drugs that target p16INK4a have the potential to inhibit its activity and reduce the growth and spread of cancer cells.
One approach to targeting p16INK4a is through the use of small interfering RNA (siRNA). SiRNA is a naturally occurring RNA molecule that can be used to knockdown the expression of specific genes, including p16INK4a.
SiRNA-concepts have been developed as potential drugs for cancer, including p16INK4a. For example, a company called Oncocyte has developed a SiRNA-based drug called OX-1002 that targets p16INK4a. OX-1002 has been shown to reduce the expression of p16INK4a in cancer cells and has been shown to have anti-tumor effects in various types of cancer animal models.
Another approach to targeting p16INK4a is through the use of RNA-fusible small interfering RNA (siRNA-RNAf) constructs. This approach allows for the delivery of RNA-II-containing miRNAs directly into cancer cells, which can then target p16INK4a for degradation.
Another potential approach to targeting p16INK4a is through the use of CRISPR/Cas9 genome editing technology. By using CRISPR/Cas9 to edit the p16INK4a gene, researchers have been able to knockdown its expression in cancer cells and have identified potential new targets for cancer therapy.
RNA-II has been shown to play a crucial role in the regulation of various diseases, including cancer. The potential drug target p16INK4a is an attractive target for cancer therapy due to its involvement in various diseases and its role in the regulation of apoptosis.
SiRNA-based drugs have been shown to be effective in targeting p16INK4a in cancer. OX-1002, a SiRNA-based drug, has been shown to reduce the expression of p16INK4a in cancer cells and has been shown to have anti-tumor effects in various types of cancer animal models.
RNA-fusible small interfering RNA (siRNA-RNAf) constructs have also shown to be effective in targeting p16INK4a in cancer. These constructs have the potential to deliver RNA-II-containing miRNAs directly into cancer cells, which can then target p16INK4a for degradation.
CRISPR/Cas9 genome editing technology has also been shown to be effective in targeting p16INK4a in cancer. By using CRISPR/Cas9 to edit the p16INK4a gene, researchers have been able to knockdown its expression in cancer cells and have identified potential new targets for cancer therapy.
Overall, RNA-II and miRNA-containing miRNAs have shown to be promising targets for cancer therapy due to their involvement in the regulation of various diseases, including cancer. The potential drug targets p16INK4a and RNA-II-containing miRNAs provide a promising avenue for cancer research and development.
Protein Name: RNA, U7 Small Nuclear 34 Pseudogene
More Common Targets
A2M | A2MP1 | A4GALT | ABAT | ABCA1 | ABCB1 | ABCB6 | ABCC5 | ABCC9 | ABCF2 | ABCG2 | ABHD11-AS1 | ABHD3 | ABI1 | ABI2 | ACAA1 | ACACA | ACAN | ACE | ACE2 | ACE3P | ACOT8 | ACP5 | ACSF3 | ACTA2-AS1 | ACTBP12 | ACTG1P12 | ACTG1P22 | ACTL10 | ACTN1-DT | ACTR1A | ACTR1B | ACTR2 | ACTR3 | ACVR2B-AS1 | ADA | ADAD2 | ADAL | ADAM1B | ADAM22 | ADAM8 | ADAMTS15 | ADAMTS16 | ADAMTS17 | ADAMTS18 | ADAMTS19 | ADAMTS9-AS2 | ADAMTSL4 | ADCY4 | ADD1 | ADD2 | ADD3 | ADD3-AS1 | ADGRA3 | ADGRE2 | ADGRF3 | ADGRG2 | ADGRL1-AS1 | ADIPOQ-AS1 | ADM5 | ADPGK-AS1 | AEBP1 | AFF1-AS1 | AFG3L1P | AFM | AFP | AFTPH | AGA | AGAP1-IT1 | AGAP11 | AGAP2-AS1 | AGAP4 | AGER | AGL | AGO3 | AGO4 | AGRP | AGT | AGTR1 | AGTR2 | AGXT | AHCY | AHI1 | AHR | AIF1 | AK6P1 | AKAP9 | AKR1C1 | AKR1C2 | AKT1 | AKT3 | ALDH1L1-AS1 | ALG14 | ALK | ALKBH4 | ALMS1-IT1 | ALOX12-AS1 | ALOX15P1 | AMN1 | ANAPC16 | ANAPC1P1 | ANKFN1 | ANKIB1 | ANKRD16 | ANKRD20A12P | ANKRD20A13P | ANKRD20A17P | ANKRD22 | ANKRD24 | ANKRD26P3 | ANKRD49 | ANKRD61 | ANKRD63 | ANKRD66 | ANLN | ANO6 | ANTXR2 | ANTXRL | ANTXRLP1 | ANXA1 | ANXA11 | ANXA13 | ANXA2 | ANXA2P1 | ANXA2P2 | ANXA2P3 | ANXA3 | ANXA4 | ANXA5 | ANXA6 | ANXA7 | AOAH | AP1B1 | AP1G1 | AP1M2 | AP1S1 | AP2A2 | AP2B1 | AP2M1 | AP2S1 | AP3S1 | AP4B1-AS1 | APBB1IP | APCDD1L | APELA | APLNR | APOBEC3A_B | APOBEC3B-AS1 | APOBEC3H | APOC4-APOC2 | APOOP2 | APPAT | APTR | AR | ARAP1-AS2 | ARFRP1 | ARHGAP19-SLIT1 | ARHGAP22-IT1 | ARHGAP26-AS1 | ARHGAP26-IT1 | ARHGAP31-AS1 | ARHGEF26-AS1 | ARHGEF33 | ARHGEF38 | ARHGEF38-IT1 | ARHGEF7-AS1 | ARID2 | ARID3A | ARL14EP | ARL15 | ARL17B | ARL2-SNX15 | ARL4A | ARL4C | ARLNC1 | ARMCX4 | ARMCX5-GPRASP2 | ARMCX6 | ARPC1B | ARPC2 | ARPC3 | ARPC4 | ARPC4-TTLL3 | ARPC5 | ARPIN-AP3S2 | ARRDC3-AS1 | ARX | ASAP1-IT2 | ASNSD1 | ASPN | ASTN2-AS1 | ASXL1 | ATAD2B | ATE1-AS1 | ATF4P4 | ATM | ATN1 | ATP11A-AS1 | ATP13A5-AS1 | ATP2A1-AS1 | ATP5PBP5 | ATP5PO | ATP6AP1 | ATP6AP2 | ATP6V0A1 | ATP6V0B | ATP6V0CP1 | ATP6V0E1P1 | ATP6V1FNB | ATP6V1G2 | ATP6V1G2-DDX39B | ATP7A | ATP7B | ATP8B1-AS1 | ATP9A | ATR | ATRX | B3GALT9 | B3GNT6 | BAALC-AS1 | BABAM2-AS1 | BACE1-AS | BANCR | BAX | BBS12 | BCAP31 | BCAR3-AS1 | BCAS2P2 | BCAS3 | BCL11A | BCL2 | BCL2L1 | BCL2L10 | BCL2L11 | BCL2L2-PABPN1 | BCO1 | BCRP7 | BECN1 | BEST2 | BHLHA15 | BHLHE40-AS1 | BICRA | BIVM | BIVM-ERCC5 | BLACAT1 | BLOC1S1-RDH5 | BLOC1S5-TXNDC5 | BMPER | BMPR1B-DT | BMS1P17 | BMS1P21 | BMS1P7 | BNC2 | BOK-AS1 | BOLA3-DT | BORCS5 | BORCS6 | BORCS7 | BORCS7-ASMT | BPIFB5P | BRAF | BRCA1 | BRINP1 | BRWD1 | BSN-DT | BSPH1 | BSPRY | BTBD1 | BTBD16 | BTG4 | BTN2A3P | BTNL10P | BYSL | C10orf71 | C10orf71-AS1 | C10orf90 | C10orf95-AS1 | C11orf24 | C11orf71 | C11orf91 | C13orf46 | C16orf82 | C16orf95 | C17orf107 | C17orf99 | C18orf54 | C1orf68 | C1QBP | C1QL2 | C1QTNF1-AS1 | C1QTNF3-AMACR | C20orf181 | C21orf58 | C21orf62-AS1 | C21orf91 | C2CD4D | C2CD4D-AS1 | C4B_2 | C4orf46P3 | C5orf52